New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:32 EDTPTCTPTC Therapeutics announces conditional EU approval of Translarna
PTC Therapeutics announced that the European Commission has granted conditional marketing authorization for Translarna, in the European Union for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. The authorization allows PTC to market Translarna in the 28 countries that are Member States of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway. As part of the conditional marketing authorization, PTC is obligated to complete its confirmatory Phase 3 trial in nmDMD and submit additional efficacy and safety data from the trial.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
11:37 EDTPTCTPTC Therapeutics CEO no longer owns company shares, TheStreet says
PTC Therapeutics CEO Stu Peltz sold the remaining 47,200 shares he owned in the company, TheStreet's Adam Feuerstein reports, citing a regulatory filing yesterday. The sale follows a stock rise in part fueled by takeover speculation, Feuerstein adds. Reference Link
March 19, 2015
08:11 EDTPTCTPTC Therapeutics and University of Pennsylvania partner for disease research
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use